April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Eplerenone fails to treat central serous chorioretinopathy
Author Affiliations & Notes
  • Harpal Sandhu
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA
  • Demetrios G Vavvas
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA
  • Footnotes
    Commercial Relationships Harpal Sandhu, None; Demetrios Vavvas, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6378. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Harpal Sandhu, Demetrios G Vavvas; Eplerenone fails to treat central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6378.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To evaluate the efficacy of the mineralocorticoid receptor antagonist eplerenone in patients with active central serous chorioretinopathy (CSR).

Methods: Retrospective case series of three patients treated with eplerenone for central serous chorioretinopathy. All patients were assessed with a full eye exam and spectral domain optical coherence tomography (SD-OCT) at each visit.

Results: Three eyes in three patients were treated with eplerenone 25 mg or 50 mg daily by mouth. All patients had decreased vision secondary to active CSR. Follow up ranged from three to 12 months. Visual acuity (VA) at the beginning of treatment ranged from 20/32 to 20/60 (mean VA 0.42). Visual acuity at one month was not significantly different (mean VA 0.49, p = 0.43), nor at the end of follow up (mean VA 0.43, p = 0.42). Central macular thickness did not change significantly from pre-treatment (mean 474 microns) to month one (mean 429 microns, p = 0.23), nor did it change significantly at the end of the follow-up period (mean 431 microns, p = 0.32).

Conclusions: Eplerenone neither reduced central macular thickness nor improved vision in this cohort of patients with central serous chorioretinopathy. More research is needed to evaluate fully the efficacy of eplerenone for this indication.

Keywords: 688 retina • 503 drug toxicity/drug effects • 585 macula/fovea  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.